Boston Scientific Buys 34% Stake in MiRus for $1.5 Billion

Published: 2026-05-18 07:05:27 ET BSX

Published on 05/18/2026 at 07:05 am EDT

By Colin Kellaher

Boston Scientific has invested $1.5 billion for a roughly 34% stake in MiRus LLC, a privately held company developing and commercializing proprietary biomaterials, implants and procedural solutions for the treatment of cardiovascular and orthopedic diseases.

Boston Scientific on Monday said the MiRus deal includes an exclusive option to buy the Siegel balloon expandable transcatheter aortic valve replacement, or TAVR, system for an additional $3 billion in cash, subject to the completion of certain milestones.

The Siegel device, which isn't yet approved for commercial distribution in any country, is built on a proprietary rhenium alloy and is the first nickel-free, balloon-expandable TAVR valve intended to restore function and normal blood flow of severely narrowed aortic valves, Boston Scientific said.

The Marlborough, Mass., medical-technology company said an exercise of the purchase option would give MiRus the right to additional payments based on sales of the Siegel TAVR valve, while Boston Scientific would have an exclusive option to buy mitral and tricuspid replacement valve assets from MiRus for an additional payment.

Write to Colin Kellaher at [email protected]

(END) Dow Jones Newswires

05-18-26 0704ET